Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 19/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17838635 | 0.95 | GPR183 (0.61) | GPR183ALDH1A1LMNATP53HPGD | |
| SCHEMBL16600581 | 0.95 | GPR183 (0.61) | GPR183ALDH1A1LMNATP53HPGD | |
| SCHEMBL16600021 | 0.90 | GPR183 (0.69) | GPR183 | |
| SCHEMBL16599834 | 0.90 | GPR183 (0.69) | GPR183 | |
| SCHEMBL16614489 | 0.87 | GPR183 (0.65) | GPR183ALDH1A1LMNATP53HPGD | |
| SCHEMBL16600172 | 0.86 | GPR183 (0.65) | GPR183 | |
| SCHEMBL16600173 | 0.86 | GPR183 (0.65) | GPR183 | |
| SCHEMBL16599921 | 0.84 | GPR183 (0.74) | GPR183 | |
| SCHEMBL16599924 | 0.84 | GPR183 (0.74) | GPR183 | |
| SCHEMBL16600103 | 0.84 | GPR183 (0.61) | GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | Sanford Burnham Prebys Medical Discovery Institute | 2016-06-23 | — | — | US | disclosed |
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | Sanford Burnham Prebys Medical Discovery Institute | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176875-A1 | SPIROCYCLIC EBI2 MODULATORS | HAVCR2, BIRC2, ESR2 | GPR183 17/4885ALDH1A1 3796/4885LMNA 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.